Five-year results from a long-term prospective study of SI-BONE’s iFuse triangular titanium implant to treat sacroiliac (SI) joint dysfunction demonstrated that improvements in pain, function and quality of life, demonstrated at two years, were durable and sustained at five years post-op.
The LOIS study assessed long-term outcomes from two previous studies: INSITE (Investigation of Sacroiliac Fusion Treatment), a U.S. randomized controlled trial and SIFI (Sacroiliac Joint Fusion with iFuse Implant System), a prospective multicenter trial. Subjects were evaluated at the study’s start (two years post-op), then again at three, four and five years. Five-year follow-up was collected for 93 subjects.
As well as durability of the clinical results, radiographic analysis of CT scans showed 98% bony apposition to implants on sacral and iliac sides of the implant, as well as a high rate of SI joint fusion with 88% bridging bone. Patient satisfaction remained high for iFuse patients, and no adverse events were reported.
Payor coverage for the iFuse implant continues to grow, with additional positive coverage announced earlier this month.
Five-year results from a long-term prospective study of SI-BONE's iFuse triangular titanium implant to treat sacroiliac (SI) joint dysfunction demonstrated that improvements in pain, function and quality of life, demonstrated at two years, were durable and sustained at five years post-op.
The LOIS study assessed long-term outcomes from two...
Five-year results from a long-term prospective study of SI-BONE’s iFuse triangular titanium implant to treat sacroiliac (SI) joint dysfunction demonstrated that improvements in pain, function and quality of life, demonstrated at two years, were durable and sustained at five years post-op.
The LOIS study assessed long-term outcomes from two previous studies: INSITE (Investigation of Sacroiliac Fusion Treatment), a U.S. randomized controlled trial and SIFI (Sacroiliac Joint Fusion with iFuse Implant System), a prospective multicenter trial. Subjects were evaluated at the study’s start (two years post-op), then again at three, four and five years. Five-year follow-up was collected for 93 subjects.
As well as durability of the clinical results, radiographic analysis of CT scans showed 98% bony apposition to implants on sacral and iliac sides of the implant, as well as a high rate of SI joint fusion with 88% bridging bone. Patient satisfaction remained high for iFuse patients, and no adverse events were reported.
Payor coverage for the iFuse implant continues to grow, with additional positive coverage announced earlier this month.
Copy to clipboard 
